It can assess patients’ suitability for Amgen’s colorectal cancer drug, Vectibix. Canadian regulatory authorities approved DxS’ TheraScreen K-RAS Mutation Kit for use as a diagnostic for anti-EGFR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback